Abstract:Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations initially respond to first generation EGFR inhibitors (such as gefitinib and elortinib), however, clinical efficacy is limited by acquired resistance, frequently driven by the EGFR T790M mutation. In this work, we identified a pyrimidine-backbone compound D7 as a novel irreversible inhibitor of EGFR T790M mutation and sensitizing mutation, with selectivity over the wild type EGFR (WT EGFR). D7 exhibited potent in vitro anti-proliferation activity in tumor cells harboring EGFR T790M (NCI-H1975 cells) and sensitizing mutations (PC-9 and HCC827 cells), whereas it showed moderate or weak inhibition in cells expressing WT EGFR. Oral administration of D7 induced dramatic tumor regression in EGFR mutated NSCLC tumor xenograft models as well as in patient-derived xenograft (PDX) model harboring EGFR T790M mutation. To further explore potential mechanisms mediating drug resistance, we constructed D7-resistant cells by prolonged exposure of parental NCI-H1975 cells to gradually increasing concentration of this compound. Resistant cells exhibited signs of apoptosis-resistance to D7 treatment and demonstrated increased sensitivity when combined with Src kinase inhibitors both in vitro and in vivo. Mechanistic investigation revealed that hyperphosphorylation of Src and subsequent activation of anti-apoptotic signaling via Akt pathway contributed to D7 resistance. These results support D7 as a promising third generation EGFR inhibitor deserving further development, and identify potential combination strategies with potential biomarkers for NSCLC tumors that is resistant to this compound. Keywords: EGFR inhibitor, lung cancer, drug resistance, combination therapy Citation Format: Tao Zhang, Rong Qu, Chengbin Chen, Linjiang Tong, Fang Feng, Yi Chen, Meiyu Geng, Ke Ding, Hua Xie, Jian Ding. Discovery of a novel third generation EGFR TKI and identification of its potential mechanism of resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2210.

Supplementary Figure 8 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 9 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 5 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 3 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 1 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 11 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 7 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 6 from Discovery of a Mutant-Selective Covalent Inhibitor of EGFR That Overcomes T790M-Mediated Resistance in NSCLC

Supplementary Figure 5 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure 3 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Supplementary Table 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure 1 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Abstract 2078: CK-101 (RX518), a Mutant-Selective Inhibitor of EGFR That Overcomes T790M-mediated Resistance in NSCLC

Discovery of 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988), A Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Supplementary Figure 6 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Supplementary Figure 4 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Table 1 from AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

Structural Basis of Mutant-Selectivity and Drug-Resistance Related to CO-1686.

Discovery of N-((3r,4r)-4-Fluoro-1-(6-((3-Methoxy-1-Methyl-1h-Pyrazol-4-Yl)Amino)-9-M Ethyl-9h-Purin-2-Yl)Pyrrolidine-3-Yl)Acrylamide (Pf-06747775) Through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic Egfr Mutants with Selectivity over Wild-Type Egfr

Abstract 2210: Discovery of a novel third generation EGFR TKI and identification of its potential mechanism of resistance